Released Aug 1, 2019, after the close
10-Q filed Aug 7, 2019, 38 days after period end · 0001162194-19-000068
Q2 2019 · 10-Q
Revenue$28.20M$28.20M +6.7% vs Q2 2018−6.4% vs Q1 2019
Net Income-$13.75M-$13.75M N/M vs Q2 2018N/M vs Q1 2019
EPS Diluted-$0.20-$0.20 N/M vs Q2 2018N/M vs Q1 2019
Gross Profit$15,363,000+13.1%
Operating Income-$14,636,000N/M
Operating Cash Flowderived-$5,013,000N/M
Free Cash Flowderived-$5,432,000N/M
Margins · derived
Gross margin54.5%+3.1 pt vs Q2 2018
Operating margin-51.9%−3.5 pt vs Q2 2018
Net margin-48.8%+12.7 pt vs Q2 2018
What the release said
The release
Same quarter
| Metric | Q2 2019 | Q2 2018 | Q2 2017 | Q2 2016 |
|---|---|---|---|---|
| Revenue | $28.20M | $26.43M | $23.91M | $28.17M |
| Net Income | -$13.75M | -$16.24M | -$16.93M | -$18.62M |
| EPS Diluted | -$0.20 | -$0.42 | -$0.58 | -$0.64 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR